Memorial Sloan Kettering Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1884-01-01

Employees: 10K

Market Cap: -

Website: http://www.mskcc.org

Clinical Trials

A Study of Botensilimab and Balstilimab for Rectal Adenocarcinoma

Phase 2

Recruiting

Conditions: Microsatellite Stable Rectal Carcinoma
Locally Advanced Rectal Adenocarcinoma

Interventions: Drug: Balstilimab
Drug: Botensilimab

First Posted Date: 2025-02-25

Last Posted Date: 2025-05-22

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 40

Registration Number: NCT06843434

Locations: 🇺🇸
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey, United States

and more 4 locations

A Study of Mirdametinib in Combination With Palbociclib in People With Liposarcoma

Phase 1

Recruiting

Conditions: Well Differentiated Liposarcoma
Dedifferentiated Liposarcoma
Liposarcoma
Myxoid Liposarcoma
Round Cell Liposarcoma
Myxoid Pleomorphic Liposarcoma
Pleomorphic Liposarcoma
Unresectable Liposarcoma
Unresectable Dedifferentiated Liposarcoma

Interventions: Drug: Mirdametinib
Drug: Palbociclib

First Posted Date: 2025-02-25

Last Posted Date: 2025-06-03

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 54

Registration Number: NCT06843967

Locations: 🇺🇸
Memorial Sloan Kettering Nassau (Limited Protocol Activities), Uniondale, New York, United States
🇺🇸
Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States

and more 4 locations

A Study of Abemaciclib and Cabozantinib in People With Clear Cell Renal Cell Carcinoma (ccRCC)

Phase 1

Recruiting

Conditions: Metastatic Renal Cell Carcinoma

Interventions: Drug: Abemaciclib
Drug: Cabozantinib

First Posted Date: 2025-02-19

Last Posted Date: 2025-02-19

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 43

Registration Number: NCT06835972

Locations: 🇺🇸
Johns Hopkins University (Data Collection Only), Baltimore, Maryland, United States
🇺🇸
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States

and more 5 locations

An Acupuncture Study for Breast Cancer Survivors With Joint Pain on Hormonal Therapies

Not Applicable

Recruiting

Conditions: Breast Cancer
Breast Cancer Female
Breast Cancer Stage I
Breast Cancer Stage II
Breast Cancer Stage III
Breast Cancer Stage IIIB
Breast Cancer Stage IIIc
Breast Cancer, Male

First Posted Date: 2025-02-07

Last Posted Date: 2025-05-22

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 60

Registration Number: NCT06814977

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center (All protocol activites), New York, New York, United States
🇺🇸
Jamaica Hospital Medical Center, Richmond Hill, New York, United States

A Study of Sotorasib in People With Brain Tumors

Phase 1

Recruiting

Conditions: Brain Tumor

Interventions: Drug: Sotorasib

First Posted Date: 2025-02-04

Last Posted Date: 2025-05-22

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 16

Registration Number: NCT06807619

Locations: 🇺🇸
Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Commack (Limited Protocol Activities), Commack, New York, United States

and more 4 locations

A Study of Valemetostat in Combination With Atezolizumab in People With Lung Cancer

Phase 1

Recruiting

Conditions: Extensive-stage Small-cell Lung Cancer

Interventions: Drug: Valemetostat
Drug: Atezolizumab

First Posted Date: 2025-02-04

Last Posted Date: 2025-02-04

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 24

Registration Number: NCT06807632

Locations: 🇺🇸
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey, United States

and more 4 locations

A Study of SER-155 to Treat Diarrhea in People on Immunotherapy

Phase 1

Recruiting

Conditions: Diarrhea
Enterocolitis

Interventions: Biological: SER-155

First Posted Date: 2025-01-30

Last Posted Date: 2025-03-04

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 15

Registration Number: NCT06801067

Locations: 🇺🇸
Memoral Sloan Kettering at Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Monmouth (All Protocol Activities), Middletown, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Bergen (All Protocol Activities), Montvale, New Jersey, United States

and more 4 locations

A Study of Breast Cancer Risk Factors and Outcomes of People in Florida

Recruiting

Conditions: Breast Cancer
Breast Neoplasms
Breast Diseases

First Posted Date: 2025-01-17

Last Posted Date: 2025-05-16

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 750

Registration Number: NCT06780176

Locations: 🇺🇸
University of California, Los Angeles (Specimen Analysis only), Los Angeles, California, United States
🇺🇸
Memorial Sloan Kettering Cancer Center (All protocol activites), New York, New York, United States

A Study of Ruxolitinib in Combination With Ulixertinib in People With Myelofibrosis

Phase 1

Recruiting

Conditions: Myelofibrosis

Interventions: Drug: Ulixertinib
Drug: Ruxolitinib

First Posted Date: 2025-01-14

Last Posted Date: 2025-01-14

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 37

Registration Number: NCT06773195

Locations: 🇺🇸
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Nassau (Limited Protocol Activities), Uniondale, New York, United States

and more 6 locations

A Study of Azacitidine and Venetoclax in People With Acute Myeloid Leukemia (AML)

Phase 2

Recruiting

Conditions: Acute Myeloid Leukemia (AML)

Interventions: Drug: Azacitidine (AZC)
Drug: Venetoclax

First Posted Date: 2025-01-14

Last Posted Date: 2025-01-14

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 30

Registration Number: NCT06773208

Locations: 🇺🇸
Memorial Sloan Kettering at Basking Ridge (All Protocol Activities), Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Monmouth (All Protocol Activities), Middletown, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Bergen (All Protocol Activities), Montvale, New Jersey, United States

and more 4 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy